New Developments in the Pharmacological Treatment of Hypertension: Dead-End or a Glimmer at the Horizon?

Current Hypertension Reports

Volumn 17, Issue 6, 2015, Pages

  Paulis, Ludovit ^a,b   Rajkovicova, Romana ^a   Simko, Fedor ^a,c  

^a Faculty of Natural Sciences   (Slovakia)

^b INSTITUTE OF CHEMISTRY   (Slovakia)

^c INSTITUTE OF EXPERIMENTAL ENDOCRINOLOGY   (Slovakia)

Author keywords

Angiotensin AT2 receptor; Angiotensin peptides; Drug combination; Hypertension; Neprilysin; Renin angiotensin aldosterone system

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN RECEPTOR; N ETHYLCARBAMOYL 3 [4 (5 FORMYL 4 METHOXY 2 PHENYL 1 IMIDAZOLYLMETHYL)PHENYL] 5 ISOBUTYL 2 THIOPHENESULFONAMIDE; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE RECEPTOR A; PHOSPHODIESTERASE; PHOSPHODIESTERASE V INHIBITOR; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOPEPTIDASE INHIBITOR; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG COMBINATION;

ANTIHYPERTENSIVE THERAPY; CLINICAL TRIAL (TOPIC); ENZYME INHIBITION; HUMAN; HYPERTENSION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; ANIMAL; BLOOD PRESSURE; DRUG COMBINATION; DRUG EFFECTS;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG COMBINATIONS; HUMANS; HYPERTENSION; RENIN-ANGIOTENSIN SYSTEM;

EID: 84928633234     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-015-0557-x     Document Type: Review

References (116)

1. Mancia G, Fagard R, Narkiewicz K, et al. ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159–219.
2. Redon J, Olsen MH, Cooper RS, et al. Stroke mortality and trends from 1990 to 2006 in 39 countries from Europe and Central Asia: implications for control of high blood pressure. Eur Heart J. 2011;32:1424–31.
3. The Pharmaceutical Research and Manufacturers of America (PhRMA). 2013 Report: Medicines in Development for Heart Disease and Stroke. In: Medicines in Development. PhRMA., 2015. http://www.phrma.org/sites/default/files/pdf/Heart_2013.pdf. Accessed 1 Mar 2015.
4. CenterWatch. FDA Approved Drugs for Cardiology/Vascular Diseases. In: FDA Approved Drugs by Therapeutic Area. CenterWatch. 2015. http://www.centerwatch.com/drug-information/fda-approvals/drug-areas.aspx?AreaID=1. Accessed 1 Mar 2015.
5. Paulis L, Unger T. Novel therapeutic targets for hypertension. Nat Rev Cardiol. 2010;7:431–41.
6. Corti R, Burnett Jr JC, Rouleau JL, et al. Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation. 2001;104:1856–62.
7. Norton GR, Woodiwiss AJ, Hartford C, et al. Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects. Am J Hypertens. 1999;12:563–71.
8. Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation. 2002;106:920–6.
9. Tabrizchi R. Omapatrilat. Bristol-Myers Squibb. Curr Opin Investig Drugs. 2001;2:1414–22.
10. Tabrizchi R. Ilepatril (AVE-7688), a vasopeptidase inhibitor for the treatment of hypertension. Curr Opin Investig Drugs. 2008;9:301–9.
11. Azizi M, Bissery A, Peyrard S, et al. Pharmacokinetics and pharmacodynamics of the Vasopeptidase inhibitor AVE7688 in humans. Clin Pharmacol Ther. 2006;79:49–61.
12. Ruilope LM, Dukat A, Böhm M, et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375:1255–66. Pivotal study investigating the effects of the angiotensin receptor/neprilysin inhibitor, LCZ696 in 1328 patients with mild to moderate hypertension. After eight weeks of treatment, 200 mg and 400 mg LCZ696 reduced sitting systolic and diastolic blood pressure more than the corresponding valsartan doses. No angioedema was reported in the LCZ696 arm.
13. Kario K, Sun N, Chiang FT, et al. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study. Hypertension. 2014;63:698–705.
14. Solomon SD, Zile M, Pieske B, et al. Prospective comparison of ARNI with ARB on Management Of heart failure with preserved ejection fraction (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380:1387–95.
15. Voors AA, Gori M, Liu LC, Claggett B, et al. Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. Eur J Heart Fail. 2015. doi:10.1002/ejhf.232.
16. Jhund PS, Claggett B, Packer M, et al. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial. Eur J Heart Fail. 2014;16:671–7.
17. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004. An angiotensin receptor/neprilysin inhibitor, LCZ696, trial in patients with heart failure with reduced ejection fraction. Compared to enalapril treatment, LCZ696 reduced the primary end-point by 20%, all-cause mortality by 16% and cardiovascular mortality by 20% leading to premature stop of the trial due to a prevailing benefit in the experimental arm.
18. Packer M, McMurray JJ, Desai AS, et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015;131:54–61.
19. McMurray J, Packer M, Desai A, et al. A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. Eur Heart J. 2015;36:434–9.
20. von Lueder TG, Wang BH, Kompa AR, et al. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. Circ Heart Fail. 2015;8:71–8.
21. Williams B, Cockcroft JR, Kario K, et al. Rationale and study design of the prospective comparison of angiotensin receptor neprilysin inhibitor with angiotensin receptor blocker measuring arterial stiffness in the eldERly (PARAMETER) study. BMJ Open. 2014;4:e004254. doi:10.1136/bmjopen-2013-004254.
22. Paulis L, Steckelings UM, Unger T. Key advances in antihypertensive treatment. Nat Rev Cardiol. 2012;9:276–85.
23. Kirkby NS, Hadoke PW, Bagnall AJ, et al. The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br J Pharmacol. 2008;153:1105–19.
24. Dhaun N, Pollock DM, Goddard J, et al. Selective and mixed endothelin receptor antagonism in cardiovascular disease. Trends Pharmacol Sci. 2007;28:573–9.
25. Feldstein C, Romero C. Role of endothelins in hypertension. Am J Ther. 2007;14:147–53.
26. Weber MA, Black H, Bakris G, et al. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: randomised, double blind, placebo-controlled trial. Lancet. 2009;374:1423–31.
27. Bakris GL, Lindholm LH, Black HR, et al. Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension. 2010;56:824–30.
28. Wengenmayer C, Krikov M, Mueller S, et al. Novel therapy approach in primary stroke prevention: simultaneous inhibition of endothelin converting enzyme and neutral endopeptidase in spontaneously hypertensive, stroke-prone rats improves survival. Neurol Res. 2011;33:201–7.
29. Thöne-Reinke C, Simon K, Richter CM, et al. Inhibition of both neutral endopeptidase and endothelin-convertingenzyme by SLV306 reduces proteinuria and urinary albumin excretion in diabetic rats. J Cardiovasc Pharmacol. 2004;44:76–9.
30. Dickstein K, De Voogd HJ, Miric MP, et al. Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure. Am J Cardiol. 2004;94:237–9.
31. Laurent S. Daglutril for treatment of renal damage in hypertensive patients with type 2 diabetes: disappointment or hope? Lancet Diab Endocrinol. 2013;1:2–3.
32. Parvanova A, van der Meer IM, Iliev I, et al. Daglutril in Diabetic Nephropathy Study Group. Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial. Lancet Diab Endocrinol. 2013;1:19–27. A double-blind, placebo-controlled trial with an endothelin converting enzyme/neprilysin inhibitor, daglutril, in hypertensive patients with type 2 diabetes and nephropathy. Daglutril improved blood pressure control, yet without affecting albuminuria.
33. Chang LT, Sun CK, Sheu JJ, et al. Cilostazol therapy attenuates monocrotaline-induced pulmonary arterial hypertension in rat model. Circ J. 2008;72:825–31.
34. Sahin M, Alizade E, Pala S, et al. The effect of cilostazol on right heart function and pulmonary pressure. Cardiovasc Ther. 2013;31:88–93.
35. O’Donnell ME, Badger SA, Sharif MA, et al. The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. J Vasc Surg. 2009;49:1226–34.
36. Agrawal NK, Maiti R, Dash D, et al. Cilostazol reduces inflammatory burden and oxidative stress in hypertensive type 2 diabetes mellitus patients. Pharmacol Res. 2007;56:118–23.
37. Uchiyama S, Shinohara Y, Katayama Y, et al. Benefit of cilostazol in patients with high risk of bleeding: subanalysis of cilostazol stroke prevention study 2. Cerebrovasc Dis. 2014;37:296–303.
38. Lewis GD, Shah R, Shahzal K, et al. Sildenafil improves exercisecapacity and quality of life in patients with systolic heart failure andsecondary pulmonary hypertension. Circulation. 2007;116:1555–62.
39. Prisant LM. Phosphodiesterase-5 inhibitors and their hemodynamic effects. Curr Hypertens Rep. 2006;8:345–51.
40. Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil in patients on common antihypertensive therapies. Am J Cardiol. 2003;92:47–57.
41. Faria AP, Modolo R, Moreno BV, et al. Effects of PDE type 5 inhibitors on left ventricular diastolic dysfunction in resistant hypertension. Arq Bras Cardiol. 2015;104:85–9.
42. Santos RC, de Faria AP, Barbaro NR, et al. Tadalafil-induced improvement in left ventricular diastolic function in resistant hypertension. Eur J Clin Pharmacol. 2014;70:147–54.
43. Chrysant SG. Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension. Curr Hypertens Rep. 2013;15:475–83.
44. Ye VZ, Hodge G, Yong JL, et al. Vasopeptidase inhibition reverses myocardial vasoactive intestinal peptide depletion and decreases fibrosis in salt sensitive hypertension. Eur J Pharmacol. 2004;485:235–42.
45. del Rio CL, George R, Kloepfer P, et al. Vasomera™, a novel VPAC2-selective vasoactive intestinal peptide agonist, enhances contractility and decreases myocardial demand in dogs with both normal hearts and with pacing-induced dilated cardiomyopathy. J Am Coll Cardiol. 2013;61:10. An animal experiment in dogs, demosntrating the effects of the VPAC2 selective, long-lasting VIP analogue, PB1046, on myocardial contractility and demand reduction.
46. PhaseBio Pharmaceuticals Inc. PB1046 (Vasomera™). In: Clinical development pipeline. PhaseBio Pharmaceuticals Inc. 2015. http://phasebio.com/clinical-development-pipeline/vasomera/. Accessed 1 Mar 2015.
47. Pandey KN. The functional genomics of guanylyl cyclase/natriuretic peptide receptor-A: perspectives and paradigms. FEBS J. 2011;278:1792–807.
48. Edelson JD, Makhlina M, Silvester KR, et al. In vitro and in vivo pharmacological profile of PL-3994, a novel cyclic peptide (Hept-cyclo(Cys-His-Phe-d-Ala-Gly-Arg-d-Nle-Asp-Arg-Ile-Ser-Cys)-Tyr-[Arg mimetic]-NH(2)) natriuretic peptide receptor-A agonist that is resistant to neutral endopeptidase and acts as a bronchodilator. Pulm Pharmacol Ther. 2013;26:229–38.
49. Jordan R, Stark J, Huskey S, et al. Phase 1 study of the novel A-type natriuretic receptor agonist, PL-3994, in healthy volunteers. In: Poster presented at the 12th scientific meeting of the Heart Failure Society of America. Palatin Technologies. Inc. 2008. http://www.palatin.com/pdfs/HFSA%20Poster11-17%20Handout.pdf. Accessed 1 Mar 2015
50. Sica D, Jordan, R, Fischkoff SA. Phase IIa study of the NPR-agonist, PL-3994, in healthy adult volunteers with controlled hypertension. In: Poster presennted at the 13th scientific meeting of the Heart Failure Society of America. Palatin Technologies. Inc. 2009. http://www.palatin.com/pdfs/Palatin%20HSFA%2709_PO%28220%29%20HR.pdf. Accessed 1 Mar 2015.
51. Merck. Merck pipeline. In: Research. Pipeline. Merck. 2015 http://www.merck.com/research/pipeline/home.html. Accessed 1 Mar 2015.
52. Unger T, Paulis L, Sica DA. Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches. Eur Heart J. 2011;32:2739–47.
53. Unger, Steckeligs, Souza dos Santos. The Protective Arm of the Renin Angiotensin System (RAS) Functional Aspects and Therapeutic Implications 1st ed. Waltham: Elsevier. Academic Press; 2015.
54. Steckelings UM, Paulis L, Unger T, et al. Emerging drugs which target the renin-angiotensin-aldosterone system. Expert Opin Emerg Drugs. 2011;16:619–30.
55. Fischer TA, Singh K, O’Hara DS, et al. Role of AT1 and AT2 receptors in regulation of MAPKs and MKP-1 by ANG II in adult cardiac myocytes. Am J Physiol. 1998;275:906–16.
56. Gohlke P, Pees C, Unger T. AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension. 1998;31:349–55.
57. Nouet S, Nahmias C. Signal transduction from the angiotensin II AT2 receptor. Trends Endocrinol Metab. 2000;11:1–6.
58. Wan Y, Wallinder C, Plouffe B, et al. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem. 2004;47:5995–6008.
59. Steckelings UM, Paulis L, Namsolleck P, Unger T. AT2 receptor agonists: hypertension and beyond. Curr Opin Nephrol Hypertens. 2012;21:142–6.
60. Rompe F, Artuc M, Hallberg A, et al. Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB. Hypertension. 2010;55:924–31.
61. Curato C, Slavic S, Dong J, et al. Identification of noncytotoxic and IL-10-producing CD8+AT2R+ T cell population in response to ischemic heart injury. J Immunol. 2010;185:6286–93.
62. Dhande I, Ali Q, Hussain T. Proximal tubule angiotensin AT2 receptors mediate an anti-inflammatory response via interleukin-10: role in renoprotection in obese rats. Hypertension. 2013;61:1218–26.
63. Valero-Esquitino V, Lucht K, Namsolleck P, et al. Direct angiotensin AT2-receptor stimulation attenuates T-cell and microglia activation and prevents demyelination in experimental autoimmune encephalomyelitis in mice. Clin Sci. 2015;128:95–109.
64. De Miguel C, Rudemiller NP, Abais JM, et al. Inflammation and hypertension: new understandings and potential therapeutic targets. Curr Hypertens Rep. 2015;17:507.
65. Rehman A, Leibowitz A, Yamamoto N, et al. Angiotensin type 2 receptor agonist compound 21 reduces vascular injury and myocardial fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension. 2012;59:291–9. An animal study in hypertensive rats, demonstrating the anti-fibrotic effects in the arterial wall by the AT2 receptor agonist, compound 21. The effects were blood pressure independent and to some degree added to the effects of losartan when given in combination.
66. Paulis L, Becker ST, Lucht K, et al. Direct angiotensin II type 2 receptor stimulation in Nω-nitro-L-arginine-methyl ester-induced hypertension: the effect on pulse wave velocity and aortic remodeling. Hypertension. 2012;59:485–92. An animal study in hypertensive rats, demonstrating the anti-fibrotic effects in the arterial wall by the AT2 receptor agonist, compound 21. The effects were blood pressure independent and to some degree added to the effects of olmesartan when given in combination.
67. Zimlichman R. Treatment of hypertension and metabolic syndrome: lowering blood pressure is not enough for organ protection, new approach-arterial destiffening. Curr Hypertens Rep. 2014;16:479.
68. Kaschina E, Grzesiak A, Li J, et al. Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation. 2008;118:2523–32.
69. Lauer D, Slavic S, Sommerfeld M, et al. Angiotensin type 2 receptor stimulation ameliorates left ventricular fibrosis and dysfunction via regulation of tissue inhibitor of matrix metalloproteinase 1/matrix metalloproteinase 9 axis and transforming growth factor β1 in the rat heart. Hypertension. 2014;63:60–7. Animal study in rats, demonstrating the effects of the AT2 receptor agonist on myocardial remodeling after myocardial infarction.
70. Hrenak J, Arendasova K, Rajkovicova R, et al. Protective effect of captopril, olmesartan, melatonin and compound 21 on doxorubicin-induced nephrotoxicity in rats. Physiol Res. 2013;62:181–9.
71. Matavelli LC, Huang J, Siragy HM. Angiotensin AT(2) receptor stimulation inhibits early renal inflammation in renovascular hypertension. Hypertension. 2011;57:308–13.
72. Gelosa P, Pignieri A, Fandriks L, et al. Stimulation of AT2 receptor exertsbeneficial effects in stroke-prone rats: focus on renal damage. J Hypertens. 2009;27:2444–51.
73. Kemp BA, Howell NL, Gildea JJ, et al. AT2 receptor activation induces natriuresis and lowers blood pressure. Circ Res. 2014;115:388–99.
74. Iwanami J, Mogi M, Tsukuda K, et al. Possible synergistic effect of direct angiotensin II type 2 receptor stimulation by compound 21 with memantine on prevention of cognitive decline in type 2 diabetic mice. Eur J Pharmacol. 2014;724:9–15.
75. Namsolleck P, Boato F, Schwengel K, et al. AT2-receptor stimulation enhances axonal plasticity after spinal cord injury by upregulating BDNF expression. Neurobiol Dis. 2013;51:177–91.
76. Villela D, Leonhardt J, Patel N, et al. Angiotensin type 2 receptor (AT2R) and receptor Mas: a complex liaison. Clin Sci. 2015;128:227–34. Experimental study suggesting heterodimerization of the AT2 receptor and the Mas receptor as explanation for the fact that blockade of either AT2 receptor or Mas receptor blocks the effects of the other receptor as well.
77. Bader M, Santos RA, Unger T, et al. New therapeutic pathways in the RAS. J Renin Angiotensin Aldosterone Syst. 2012;13:505–8.
78. Savergnini SQ, Beiman M, Lautner RQ, et al. Vascular relaxation, antihypertensive effect, and cardioprotection of a novel peptide agonist of the MAS receptor. Hypertension. 2010;56:112–20.
79. Bertagnolli M, Casali KR, De Sousa FB, et al. An orally active angiotensin-(1–7) inclusion compound and exercise training produce similar cardiovascular effects in spontaneously hypertensive rats. Peptides. 2014;51:65–73. An animal study in spontaneously hypertensive rats, demonstrating the blood pressure reducing and antihypertrophic effects of the encapsulated Ang (1–7).
80. Fraga-Silva RA, Savergnini SQ, Montecucco F, et al. Treatment with Angiotensin-(1–7) reduces inflammation in carotid atherosclerotic plaques. Thromb Haemost. 2014;111:736–47.
81. Santos SH, Giani JF, Burghi V, et al. Oral administration of angiotensin-(1–7) ameliorates type 2 diabetes in rats. J Mol Med (Berl). 2014;92:255–65.
82. Singh Y, Singh K, Sharma PL. Effect of combination of renin inhibitor and Mas-receptor agonist in DOCA-salt-induced hypertension in rats. Mol Cell Biochem. 2013;373:189–94.
83. Barroso LC, Silveira KD, Lima CX, et al. Renoprotective effects of AVE0991, a nonpeptide mas receptor agonist, in experimental acute renal injury. Int J Hypertens. 2012;2012:808726. doi:10.1155/2012/808726.
84. Silveira KD, Barroso LC, Vieira AT, et al. Beneficial effects of the activation of the angiotensin-(1–7) MAS receptor in a murine model of adriamycin-induced nephropathy. PLoS One. 2013;8:e66082. doi:10.1371/journal.pone.0066082.
85. Rentzsch B, Todiras M, Iliescu R, Popova, et al. Transgenic angiotensin-converting enzyme 2 overexpression in vessels of SHRSP rats reduces blood pressure and improves endothelial function. Hypertension. 2008;52:967–73.
86. Zhong J, Basu R, Guo D, Chow et al. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation. 2010;122:717–28.
87. Haschke M, Schuster M, Poglitsch M, Loibner, et al. Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects. Clin Pharmacokinet. 2013;52:783–92. A phase 1 study with recombinant human ACE2, APN01, in healthy volunteers. APN01 dose-dependently reduced the Ang II levels and increased Ang (1–7) and Ang (1–5) levels, yet without any significant blood pressure effects.
88. Oudit GY, Penninger JM. Recombinant human angiotensin-converting enzyme 2 as a new renin-angiotensin system peptidase for heart failure therapy. Curr Heart Fail Rep. 2011;8:176–83.
89. Hernández Prada JA, Ferreira AJ, Katovich MJ, et al. Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension. 2008;51:1312–7.
90. Ferreira AJ, Shenoy V, Qi Y, et al. Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases. Exp Physiol. 2011;96:287–94.
91. Ferreira AJ, Shenoy V, Yamazato Y, et al. Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. Am J Respir Crit Care Med. 2009;179:1048–54.
92. Haber PK, Ye M, Wysocki J, et al. Angiotensin-converting enzyme 2-independent action of presumed angiotensin-converting enzyme 2 activators: studies in vivo, ex vivo, and in vitro. Hypertension. 2014;63:774–82.
93. Drugs@FDA. FDA Approved Drug Products. In: FDA US Food and Drug Administration. 2015. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed 1 Mar 2015.
94. Bakris GL, Sica D, White WB, et al. Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil. Am J Med. 2012;125:1229.e1-10.
95. Weber MA, White WB, Sica D, et al. Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension. Blood Press Monit. 2014;19:90–7.
96. Parving HH, Brenner BM, McMurray JJ, et al. Aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant. 2009;24:1663–71.
97. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–59.
98. Krop M, Lu X, Verdonk K, et al. New renin inhibitor VTP-27999 alters renin immunoreactivity and does not unfold prorenin. Hypertension. 2013;61:1075–82.
99. Rajagopalan S, Bakris GL, Abraham WT, et al. Complete renin-angiotensin-aldosterone system (RAAS) blockade in high-risk patients: recent insights from renin blockade studies. Hypertension. 2013;62:444–9.
100. Poglitsch M, Schwager C, Domenig O, et al. The RAS-FingerprintTM patient specific characterization of the renin-angiotensin-system. In: RAS-Fingerprint™ Proof of Concept. Attoquant diagnostics. 2015. http://www.attoquant.com/images/poc/attoquant_proof_of_concept.pdf. Accessed 1 Mar 2015.
101. Carroll MA, Kang Y, Chander PN, et al. Azilsartan is associated with increased circulating angiotensin-(1–7) levels and reduced renovascular 20-HETE levels. Am J Hypertens. 2015;28:664–71.
102. Takagi H, Mizuno Y, Niwa M, et al. A meta-analysis of randomized controlled trials of azilsartan therapy for blood pressure reduction. Hypertens Res. 2014;37:432–7.
103. Kurtz TW, Kajiya T. Differential pharmacology and benefit/risk of azilsartan compared to other sartans. Vasc Health Risk Manag. 2012;8:133–4.
104. Kajiya T, Ho C, Wang J, et al. Molecular and cellular effects of azilsartan: a new generation angiotensin II receptor blocker. J Hypertens. 2011;29:2476–83.
105. Gitt AK, Baumgart P, Bramlage P, et al. EARLY Treatment with azilsartan compared to ACE-inhibitors in anti-hypertensive therapy–rationale and design of the EARLY hypertension registry. BMC Cardiovasc Disord. 2013;13:46.
106. Lane DA, Shah S, Beevers DG. Low-dose spironolactone in the management of resistant hypertension: a surveillance study. J Hypertens. 2007;25:891–4.
107. Chapman N, Dobson J, Wilson S, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49:839–45.
108. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11–21.
109. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–21.
110. Bärfacker L, Kuhl A, Hillisch A, et al. Discovery of BAY 94–8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem. 2012;7:1385–403.
111. Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94–8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34:2453–63.
112. Schnackenberg CG, Costell MH, Krosky DJ, et al. Chronic inhibition of 11 β -hydroxysteroid dehydrogenase type 1 activity decreases hypertension, insulin resistance, and hypertriglyceridemia in metabolic syndrome. Biomed Res Int. 2013;2013:427640. doi:10.1155/2013/427640.
113. Amar L, Azizi M, Menardet J, et al. Aldosterone synthase inhibitionwith LCI699: a proof-of-concept study in patients with primary aldosteronism. Hypertension. 2010;56:831–8.
114. Calhoun DA, White WB, Krum H, et al. Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. Circulation. 2011;124:1945–55.
115. Karns AD, Bral JM, Hartman D, et al. Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension. Clin Hyperten. 2013;15:186–92.
116. Schumacher CD, Steele RE, Brunner HR, et al. Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy. J Hypertens. 2013;31:2085–93.